Kubik Pawel, Gruszczyński Wojciech, Filipowska Monika
K-LAB Badania i Rozwój, 81-312 Gdynia, Poland.
Polymers (Basel). 2025 Jun 27;17(13):1778. doi: 10.3390/polym17131778.
This study aimed to evaluate the reconstitution and solubility characteristics of two injectable poly L-lactic acid (PLLA) formulations, the next-generation injectable PLLA-LASYNPRO™ and a previous-generation PLLA (PLLA-SCA), through in vitro analysis.
The study, conducted from 20 November to 11 December 2024, involved reconstituting PLLA-LASYNPRO™ in 5 mL saline solution and PLLA-SCA in 8 mL sterile water or saline (as specified in the instructions for use). Reconstitution processes were recorded using a 4K camera, and microscopic and sieve-based analyses were performed at various time points (1-120 min). The study used standardized methods for reconstitution, observation, and sample collection, including a light microscope and micrometric sieves.
PLLA-LASYNPRO™ exhibited rapid, uniform reconstitution, resulting in a homogeneous milky-white solution with no foam formation. In contrast, PLLA-SCA showed a two-phase mixture with foam formation, requiring more vigorous shaking. Over time, PLLA-LASYNPRO™ displayed gradual sedimentation, with no foam, while PLLA-SCA showed a progressive increase in foam volume and sedimentation. Microscopic analysis revealed consistent particle morphology, with PLLA-LASYNPRO™ particles being smaller and homogeneous, and PLLA-SCA exhibiting larger, irregular particles prone to aggregation. Sieve analysis showed that PLLA-LASYNPRO™ produced minimal sediment, whereas PLLA-SCA consistently produced sediment on both 71 µm and 200 µm sieves.
PLLA-LASYNPRO™ and PLLA-SCA display distinct reconstitution behaviors, with PLLA-LASYNPRO™ showing more consistent characteristics and fewer issues with foam and sedimentation. These differences may impact clinical applications and require consideration in treatment planning.
本研究旨在通过体外分析评估两种可注射聚左旋乳酸(PLLA)制剂——新一代可注射PLLA-LASYNPRO™和上一代PLLA(PLLA-SCA)的复溶和溶解特性。
该研究于2024年11月20日至12月11日进行,涉及将PLLA-LASYNPRO™在5 mL盐溶液中复溶,以及将PLLA-SCA在8 mL无菌水或盐溶液中复溶(按照使用说明)。使用4K摄像机记录复溶过程,并在不同时间点(1 - 120分钟)进行显微镜和基于筛网的分析。该研究采用标准化的复溶、观察和样本采集方法,包括光学显微镜和测微筛。
PLLA-LASYNPRO™表现出快速、均匀的复溶,形成均匀的乳白色溶液且无泡沫形成。相比之下,PLLA-SCA呈现出两相混合物并有泡沫形成,需要更剧烈的振荡。随着时间推移,PLLA-LASYNPRO™显示出逐渐沉降,无泡沫,而PLLA-SCA的泡沫体积和沉降逐渐增加。显微镜分析显示颗粒形态一致,PLLA-LASYNPRO™颗粒较小且均匀,而PLLA-SCA呈现出较大、不规则且易于聚集的颗粒。筛网分析表明,PLLA-LASYNPRO™产生的沉淀极少,而PLLA-SCA在71 µm和200 µm筛网上均持续产生沉淀。
PLLA-LASYNPRO™和PLLA-SCA表现出不同的复溶行为,PLLA-LASYNPRO™具有更一致的特性,在泡沫和沉降方面问题较少。这些差异可能会影响临床应用,在治疗规划中需要考虑。